HopeStage
Back to all studies
Active Not RecruitingNCT06698848

Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome

Medication studyAges 18–50United StatesDepression
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 50 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 1, 2025
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
120
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT06698848
Official title
Show the full official title

Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome

Recruitment & locations

Not recruiting

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including ketamin.

Who can participate?

Listed age limits: 18 years to 50 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies